FMP
NASDAQ
1.98 USD
-0.02 (-1.01%)
Dr. Sanjay S. Shukla M.D., M.S.
Healthcare
Biotechnology
https://www.atyrpharma.com
NASDAQ
aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company's lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase II clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. It is also developing ATYR2810, a fully humanized monoclonal antibody that is in preclinical development for the treatment of solid tumors. It has collaboration and license agreement with Kyorin Pharmaceutical C...
0001339970
US0021202025
002120202
3545 John Hopkins Court
858 731 8389
US
56
May 7, 2015
0001339970
NASDAQ
Biotechnology
Healthcare
002120202
US0021202025
US
1.98
1.25
547.02k
134.15M
-
1.08-2.7
0.12
-
-
-
-
-2.11
-
https://www.atyrpharma.com
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
It looks like there's no news available.